Spots Global Cancer Trial Database for Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Official Title: A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Study ID: NCT01123876
Conditions
Interventions
Study Description
Brief Summary: Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 24987, Scottsdale, Arizona, United States
Site Reference ID/Investigator# 24985, Los Angeles, California, United States
Site Reference ID/Investigator# 26742, Los Angeles, California, United States
Site Reference ID/Investigator# 24986, Washington, District of Columbia, United States
Site Reference ID/Investigator# 24922, Durham, North Carolina, United States
Site Reference ID/Investigator# 24983, Nashville, Tennessee, United States
Site Reference ID/Investigator# 75713, Seoul, , Korea, Republic of
Site Reference ID/Investigator# 75714, Seoul, , Korea, Republic of
Contact Details
Name: Stacie Shepherd, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
